Drugs to treat dementia and psychosis

Movement Disorders

Volumn 17, Issue SUPPL. 4, 2002, Pages

  Goetz, C G ^a   Koller, W C ^a   Poewe, W ^a   Rascol, O ^a   Sampaio, C ^a   Brin, M F ^a   Lees, Andrew J ^a   LeWitt, P ^a   Lozano, A ^a   Mizuno, Y ^a   Nutt, J ^a   Oertel, W ^a   Olanow, C W ^a   Tolosa, E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMANTADINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; HISTAMINE H1 RECEPTOR; HISTAMINE RECEPTOR; LEVODOPA; MIANSERIN; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SEROTONIN 2 RECEPTOR; TACRINE; ZOTEPINE;

CLINICAL TRIAL; CONFUSION; DEMENTIA; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG URINE LEVEL; EXTRAPYRAMIDAL SYMPTOM; FIRST PASS EFFECT; HALLUCINATION; HUMAN; LOW DRUG DOSE; MEMORY DISORDER; META ANALYSIS; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR BINDING; REVIEW; SEDATION; SYMPTOMATOLOGY; TREMOR; VERTIGO; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS;

EID: 0036929986     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.5573     Document Type: Review

References (53)

1. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106:257-270.
2. Ransmayr G, Schmidhuber-Eiler B, Karamat E, et al. Visuopercertion and visuospatial and visuorotational perform in Parkinson's disease. J Neurol 1987;235:99-101.
3. Artieda J. Pastor MA, Lacruz F, Obeso JA. Temporal discrimination is abnormal in Parkinson's disease. Brain 1992;115:199-210.
4. Brown RG, Marsden CD. Cognitive function in Parkinson's disease: from description to theory. Trends Neurosci 1990;13:21-29.
5. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol 1987;44:S1-S9.
6. McKeith IG, Galakso D, Kosaka K, Perry EK, et al. Consensus guidelines for the clinical and pathological of dementia with Lewy Bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
7. Schrag A, Ben-Shlomo Y, Brown R, Marsden DC, Quinn N. Young-onset Parkinson's disease revisited-clinical features, nature history, and mortality. Mov Disord 1998;13:885-894.
8. Hughes Aj, Daniel SE, Blankson S, Lees AJ. A Clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-148.
9. Mckeith I, Del Ser T, Spano P, Emre M, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
10. Hutchinson M, Farrizi E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:324-325.
11. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapautic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom. BMJ 1993;307:469-472.
12. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interin report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998;13:39-45.
13. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997;48:363-368.
14. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995;65:115-138.
15. Friedman JH. Management of psychosis in Parkinson's disease. In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. New York: Marcel Dekker; 1995. p. 521-532.
16. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucination in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 2000;123:733-745.
17. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
18. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine. Comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:748-749.
19. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
20. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991;324:746-754.
21. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614.
22. Scholz E, Dichgans J. Treatment of drug-induced exogeneous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985;235:60-64.
23. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999;340:757-763.
24. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet 1999;353:2041-2042.
25. Wagner ML, Defilippi JL, Menza MA, Sage JI. Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996;8:276-280.
26. Ruggieri S, De-Pandis MF, Bonamartini A, Vacca L, Stocchi F. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin Neuropharmacol 1997;20:204-209.
27. Widman LP, Burke WJ, Pfeiffer RF, McArthur CD. Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: retrospective review. J Geriatr Psychiatry Neurol 1997;10:63-66.
28. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-1845.
29. Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine [letter]. Lancet 2000;355:1155-1156.
30. Elias TJ, Bannister KM, Clarkson AR, Faull D, Faull RJ. Clozapine-induced acute interstitial nephritis [letter]. Lancet 1999;354:1180-1181.
31. The European Agency for the Evaluation of Medical Products. Zyprexa, International Nonproprietary Name (INN): Olanzapine. Committee for Proprietary Medicinal Products. European Public Assessment Report (EPAR). CPMP/646-96. 1996. (GENERIC) Ref Type: Report.
32. Aarsland D, Larsen JP, Lim NG, Tandberg E. Olanzipine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci 1999;11:392-394.
33. Graham JM, Sussman JD, Ford KS, Sagar HJ. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J Neurol Neurosurg Psychiatry 1998;65:774-777.
34. Friedman J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease [letter; comment]. Neurology 1998;50:1195-1196.
35. Friedman JH, Goldstein S, Jacques C. Substituting clozapine for olanzapine in in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol 1998;21:285-288.
36. Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine [In Process Citation]. Mov Disord 1999;14:1014-1016.
37. Wolters EC, Jansen EN, Tuynman QH, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-1087.
38. Benedetti F, Cavallaro R, Smeraldi E. Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet 1999;354:567.
39. Naumann R, Felber W, Heilemann H, Reuster T. Olanzapine-induced agranulocytosis. Lancet 1999;354:566-567.
40. Meissner W, Schmidt T, Kupsch A, Trottenberg T, Lempert T. Reversible leucopenia related to olanzapine. Mov Disord 1999;14:872-889.
41. Matheson AJ, Lamb HM. Quetiapine. A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease. CNS Drugs 2000;14:157-172.
42. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999;14:484-487.
43. Fernandez HH. Quetiapine for l-dopa-induced psychosis in PD. Neurology 2000;55:899.
44. Weiner WJ, Minagar A, Shulman LM. Quetiapine for l-dopa-induced psychosis in PD. Neurology 2000;54:1538.
45. Dewey RB, O'Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 2000;55:1753-1754.
46. Menza MM, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry 1999;11:141-144.
47. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol. 2000;20:54-60.
48. Parsa MA, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998;10:216-219.
49. Meco G, Alessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients [letter]. Lancet 1997;343:1370-1371.
50. Zoldan J, Friedberg G, Goldberg SH, Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease [letter]. Lancet 1993;341:562-563.
51. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron. a 5-HT3 receptor antagonist. Neurology 1995;45:1305-1308.
52. Zoldan J, Friedberg G, Weizman A, Melamed E. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Adv Neurol 1996;69:541-544.
53. Friedberg G, Zoldan J, Weizman A, Melamed E. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 1998;21:280-284.